Compare REX AI Equity Premium Income ETF (AIPI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Regeneron Pharmaceuticals Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.25, while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while REX AI Equity Premium Income ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | REGN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $812.27 |
52-Week Low | $32.45 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.34, up 1.52% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock pays high weekly dividends, recently transitioning to this frequency to attract income investors. Key resistance lies at $38, with support at $36.
Outlook is mixed: high dividend yields near 35% offer income appeal, but sustainability concerns and structural risks from option-writing strategies pose challenges. Investors should weigh income benefits against potential NAV erosion if AI market momentum slows.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
